CINGW
Price:
$0.085
Market Cap:
$15.61M
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.[Read more]
Industry
Biotechnology
IPO Date
Stock Exchange
NASDAQ
Ticker
CINGW
According to Cingulate Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.05. This represents a change of -79.27% compared to the average of -0.24 of the last 4 quarters.
The mean historical PE Ratio of Cingulate Inc. over the last ten years is -2.75. The current -0.05 PE Ratio has changed 81.96% with respect to the historical average. Over the past ten years (40 quarters), CINGW's PE Ratio was at its highest in in the September 2024 quarter at -0.00. The PE Ratio was at its lowest in in the September 2020 quarter at -11.03.
Average
-2.75
Median
-1.50
Minimum
-6.91
Maximum
-0.29
Discovering the peaks and valleys of Cingulate Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 57.13%
Maximum Annual PE Ratio = -0.29
Minimum Annual Increase = -78.22%
Minimum Annual PE Ratio = -6.91
Year | PE Ratio | Change |
---|---|---|
2023 | -0.29 | -53.56% |
2022 | -0.63 | -57.90% |
2021 | -1.50 | -78.22% |
2020 | -6.91 | 57.13% |
The current PE Ratio of Cingulate Inc. (CINGW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-0.81
5-year avg
-2.75
10-year avg
-2.75
Cingulate Inc.’s PE Ratio is less than Cingulate Inc. (-0.00), greater than Celularity Inc. (-1.43), greater than NeuroSense Therapeutics Ltd. (-2.03), greater than EQRx, Inc. (-7.28), greater than Dermata Therapeutics, Inc. (-0.18),
Company | PE Ratio | Market cap |
---|---|---|
-0.00 | $15.61M | |
-1.43 | $52.39M | |
-2.03 | $28.91M | |
-7.28 | $1.14B | |
-0.18 | $2.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cingulate Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cingulate Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cingulate Inc.'s PE Ratio?
How is the PE Ratio calculated for Cingulate Inc. (CINGW)?
What is the highest PE Ratio for Cingulate Inc. (CINGW)?
What is the 3-year average PE Ratio for Cingulate Inc. (CINGW)?
What is the 5-year average PE Ratio for Cingulate Inc. (CINGW)?
How does the current PE Ratio for Cingulate Inc. (CINGW) compare to its historical average?